Merck Mercuriadis, founder of the influential catalog investment group Hipgnosis, is preparing to launch a re-vamped version ...

Merck Mercuriadis aims to buy back the music rights he sold to the private equity firm while building a new investment ...

Merck Mercuriadis, the architect behind Hipgnosis’s transformation of music rights into a mainstream asset class, is making a ...

Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...

Explore the Hipgnosis founder's new venture, focused on music management and co-ownership for artists and managers.

I've written this kind of article before, addressing whether it's smart to buy into the dividend-paying stocks in the S&P 500 ...

Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertiseVANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- ...

Jazz Pharmaceuticals plc is a Buy with its robust portfolio, potential FDA approvals, and innovative oncology treatments.

With funding cuts threatening global immunization, philanthropic organizations are stepping up but warn they can’t fill the ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

A new study finds high cholesterol is being widely undertreated, leading to tens of thousands of needless heart attacks and ...

TGCT is a rare condition that originates in the synovial lining of joints, bursae and tendon sheaths. With an incidence rate of just one in 20,000 -- it has been included in China's catalog of rare ...